A randomized prospective trial comparing cyclosporine monotherapy with triple-drug therapy in renal transplantation
- PMID: 1858154
- DOI: 10.1097/00007890-199107000-00011
A randomized prospective trial comparing cyclosporine monotherapy with triple-drug therapy in renal transplantation
Abstract
In a prospective trial 151 recipients of renal transplants were randomly assigned to treatment with CsA alone (74 patients) and to low dose of AZA, prednisolone, and CsA (77 patients). At two years, graft survival was 84% for the monotherapy and 90% for the triple therapy. This difference was not statistically significant. The number of rejection episodes was similar in the two groups, but the severity of rejection was significantly worse among the patients on monotherapy. More kidneys were lost because of rejection (6 versus 3), and a higher number of methylprednisolone pulses was used for treating rejection (5.2 +/- 2.3 versus 4.3 +/- 2.9; P = 0.0077). CsA nephrotoxicity episodes were more frequent among patients on monotherapy (23 versus 7; P less than 0.02). Infectious episodes were equally distributed between the two groups. Creatinine clearance was poorer in the monotherapy-treated patients at the third month (42 +/- 16 ml/min versus 48 +/- 15 ml/min; P = 0.02), but no differences were observed between the two groups since the sixth month after transplantation. Many patients on monotherapy required changes in maintenance therapy. In fact, one patient was switched to conventional immunosuppression because of Cremophor-induced anaphylaxis. Another patient who developed Kaposi's sarcoma 4 months after surgery was switched to steroids alone. Excluding 5 patients who lost their grafts a few days after transplantation, only 30 of 74 patients (40%) could be kept without steroids. We conclude that both the therapeutic protocols can give good results in renal allotransplantation; however, monotherapy could create some problems in keeping the balance between drug toxicity and significant immunosuppression. On the contrary, triple therapy is easier to handle, especially in the early posttransplant period when the differential diagnosis between acute rejection and CsA-related nephrotoxicity can be difficult even for a skilled clinician.
Similar articles
-
Minimization of maintenance immunosuppressive therapy after renal transplantation comparing cyclosporine A/azathioprine or cyclosporine A/mycophenolate mofetil bitherapy to cyclosporine A monotherapy: a 10-year postrandomization follow-up study.Transpl Int. 2016 Jan;29(1):23-33. doi: 10.1111/tri.12627. Transpl Int. 2016. PMID: 26729582 Clinical Trial.
-
A randomized trial comparing triple-drug and double-drug therapy in renal transplantation.Transplantation. 1988 May;45(5):913-8. doi: 10.1097/00007890-198805000-00014. Transplantation. 1988. PMID: 3285536 Clinical Trial.
-
Results of the Minnesota randomized prospective trial of cyclosporine versus azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients.Am J Kidney Dis. 1985 Jun;5(6):318-27. doi: 10.1016/s0272-6386(85)80161-x. Am J Kidney Dis. 1985. PMID: 3893106 Clinical Trial.
-
[Value of a powerful initial immunosuppression after liver transplantation. Prospective study of 60 cases].Gastroenterol Clin Biol. 1994;18(2):115-22. Gastroenterol Clin Biol. 1994. PMID: 8013792 Review. French.
-
Therapeutic monitoring for cyclosporine: difficulties in establishing a therapeutic window.Clin Biochem. 1991 Feb;24(1):81-7. doi: 10.1016/0009-9120(91)90315-6. Clin Biochem. 1991. PMID: 2060137 Review.
Cited by
-
Immunosuppressive drugs in renal transplantation. A review of the regimens.Drugs. 1992 Oct;44(4):554-66. doi: 10.2165/00003495-199244040-00003. Drugs. 1992. PMID: 1281071 Review.
-
A review of landmark studies on maintenance immunosuppressive regimens in kidney transplantation.Asian Biomed (Res Rev News). 2024 Jun 28;18(3):92-108. doi: 10.2478/abm-2024-0015. eCollection 2024 Jun. Asian Biomed (Res Rev News). 2024. PMID: 39175954 Free PMC article. Review.
-
Tacrolimus rescue therapy for renal transplant rejection.Transplant Proc. 1996 Aug;28(4):2119-20. Transplant Proc. 1996. PMID: 8769174 Free PMC article. Clinical Trial. No abstract available.
-
Calcineurin inhibitors in renal transplantation: what is the best option?Drugs. 2003;63(15):1535-48. doi: 10.2165/00003495-200363150-00002. Drugs. 2003. PMID: 12887261 Review.
-
Corticosteroids in kidney transplant recipients. Safety issues and timing of discontinuation.Drug Saf. 1995 Sep;13(3):145-56. doi: 10.2165/00002018-199513030-00002. Drug Saf. 1995. PMID: 7495501 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical